Skip to main content

InvestorNewsBreaks – RYAH Group Inc. (CSE: RYAH) Signs LOI to Develop Delivery Solutions for Psychoactive Compounds

RYAH Group (CSE: RYAH), a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, is partnering with Emotional Intelligence Ventures (Ei.Ventures), a leading psychedelic formulation and therapeutic research company. The collaboration is designed to evaluate the compatibility of RYAH’s proprietary Smart Patch delivery and monitoring device, software and data platform with Ei.Ventures’ proprietary psychedelic formulations. In addition, the two companies will work together on advancing Ei.Ventures’ research and development strategy. The partnership takes the two companies a step closer to negotiating and finalizing certain definitive research and development (R&D), licensing  and distribution agreements. “This marks a new era for RYAH Group, as we look to expand our non-medicine touching technologies and treatments to support industry partners engaged in the psychedelics markets, in addition to medical cannabis,” said RYAH CEO Gregory Wagner in the press release. “Our cutting-edge devices and data analytics are designed to work with a wide range of plant-based medicines, making it a logical next step for the Company to partner with Ei.Ventures, which is a leader in psychedelic research, formulation and mental healthcare.”

To view the full press release, visit

About RYAH Group Inc.

RYAH Group is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies, as well as licensed processors (“LPs”) to monitor and manage formulation effects on patients and demographics. RYAH gathers deep and insightful data on the complete patient session and formulation life cycle. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.